3071 – RESOLVIN E1 IMPROVES EFFEROCYTOSIS AND PROTECTS AGAINST IMMUNE-MEDIATED BONE MARROW FAILURE IN MICE

Rachel Grazda,Allison Seyfried,Katherine MacNamara
DOI: https://doi.org/10.1016/j.exphem.2023.06.178
IF: 3.249
2023-01-01
Experimental Hematology
Abstract:Severe aplastic anemia (SAA) is a rare, fatal form of bone marrow (BM) failure characterized by a profound loss of hematopoietic stem cells (HSCs) and a failure to produce blood and immune cells. Current treatments for SAA rely on HSC transplantation and immunosuppressive therapies, though these treatments are not always effective. Immune-mediated destruction and inflammation of the BM are well-known drivers of SAA, but the underlying molecular mechanisms that lead to persistent inflammation are unknown. Using an established, preclinical murine model of SAA, we observed a significant increase in apoptotic and dead BM cells expressing CD47, a “don't eat me” signal. Increased CD47 correlated with a novel population of BM monocytes that expressed significantly increased signal regulatory protein alpha (SIRPa). Binding of CD47 to SIRPa on phagocytes inhibits clearance of apoptotic cells, or efferocytosis. Consistent with elevated CD47 and SIRPa, BM myeloid cells in SAA mice exhibited a significant reduction in efferocytosis, and neutralizing antibodies to SIRPa improved cell clearance. As efferocytosis is important for the resolution of inflammation, we next examined the production of pro-inflammatory and pro-resolving lipid mediators. Lipidomic analysis of the BM revealed imbalanced lipid mediators, with reduced precursors of specialized pro-resolving lipid mediators (SPMs), and increased prostaglandins, indicative of impaired inflammation resolution. Specifically, significantly reduced 18-HEPE, a precursor of E-series resolvins, was observed in SAA mice. Treatment with exogenous Resolvin E1 (RvE1) improved survival, BM cellularity, platelet output, and efferocytic function. Our data suggest that aberrant inflammation resolution contributes to SAA and demonstrates that SPMs, such as RvE1, may offer new strategies to treat disease that do not rely on immune suppression.
medicine, research & experimental,hematology
What problem does this paper attempt to address?